Quantity | = | Concentration | x | Volume | x | Molecular Weight |
---|---|---|---|---|---|---|
= | x | x |
1) Click the Molarity Calculation Cart® button.
2) Specify the Concentration and Volume of your desired Molarity.
3) Click Calculate.
4) Your desired Quantity will be calculated and will be put under Quantity: (only for mg)
5) Click Add to Cart and then Proceed to checkout to complete the order. You will receive the quantity as you ordered as solvent-free form.
Alert: If you want to make a solution with a solvent (such DMSO), please add instructions in the notes section (such as 10 nM/1 mL in DMSO) and we will pack and deliver the product as a solution (such as 10 nM solution in 1 mL DMSO). If the product cannot be dissolved in DMSO or you would like to specify your own preferred solvent, please add detailed instructions in the notes section. All solutions must be shipped with an ice bag, costing an additional fee of $20 for S&H.
AOB16508
CAS 1616428-23-9
Chemical Name: CG806; CG026806; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(2,4,6-trifluorophenyl)urea
Warning: Last items in stock!
Availability date:
Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
---|---|---|---|
1 | 100 | $58.05 | Total: $5,805.00 |
1 | 50 | $67.08 | Total: $3,354.00 |
1 | 25 | $78.69 | Total: $1,967.25 |
1 | 10 | $92.88 | Total: $928.80 |
1 | 5 | $109.65 | Total: $548.25 |
Molecular Formula | C25H17F4N5O2 |
Molecular Weight | 495.43 |
CAS Numbers | 1616428-23-9 |
Storage Condition | 0°C (short term), -20°C (long term), desiccated |
Solubility | DMSO |
Purity | 98% by HPLC |
Synonym | CG806; CG026806 |
IUPAC/Chemical Name | 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(2,4,6-trifluorophenyl)urea |
SMILES Code | O=C(NC1=C(F)C=C(F)C=C1F)NC2=CC(F)=C(C(C=CC(C3=NC(C)=CN3)=C45)=C5CNC4=O)C=C2 |
References | 1) Ekaterina Kim MS, et al. CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells. bloodjournal Blood blood (2019). 134 (Supplement_1) : 3051. 2) Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes |
Novel potent pan-FLT3/pan-BTK inhibitor, inhibiting wild type and many of the clinically relevant mutant forms of FLT3 at low nanomolar concentrations, targeting FLT3 and clusters of kinases operative in acute myeloid leukemia